Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 14/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698117 | 0.87 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL1573281 | 0.84 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL2468822 | 0.83 | NISCH (0.41) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL698495 | 0.81 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL696820 | 0.81 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL697375 | 0.78 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| SCHEMBL697119 | 0.76 | NISCH (0.52) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| Demiditraz SCHEMBL29388955 | 0.75 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| Demiditraz SCHEMBL697081 | 0.75 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CNISCHF2RL1 | |
| Demiditraz SCHEMBL696353 | 0.75 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CNISCHF2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320732-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | Pfizer Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010020896-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-18 | — | — | US | claimed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-2320732-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | Pfizer Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| WO-2010020896-A2 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| EP-1981853-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | Pfizer Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| WO-2007083207-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ADRA2A 456/4885ADRA2B 317/4885ADRA2C 144/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ADRA2A 456/4885ADRA2B 317/4885ADRA2C 144/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ADRA2A 456/4885ADRA2B 317/4885ADRA2C 144/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ADRA2A 456/4885ADRA2B 317/4885ADRA2C 144/4885 |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | ING2, IGFBP2, IGFBP1 | ADRA2A 3171/4885ADRA2B 2195/4885ADRA2C 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.